Tags : Previously Untreated

AbbVie’s Dual Regimen Receives EC’s Approval for Patients with Previously

Shots: The approval is based on P-III CLL14 study assessing Venclyxto (venetoclax) + obinutuzumab vs obinutuzumab + chlorambucil in 432 patients with previously untreated CLL and coexisting medical condition The P-III CLL14 study results: median follow up @28mos. superior PFS; @40mos. median PFS had not been reached (35.6mos.); @36mos. PFS (81.9% vs 49.5%) @1yr. patients […]Read More

Roche Reports Results of Triple Combination Regimen in P-III IMspire150

Shots: The P-III IMspire150 study involves assessing of Tecentriq (atezolizumab) + Cotellic (cobimetinib) + Zelboraf (vemurafenib) vs PBO+ Cotellic + Zelboraf in patients with previously untreated BRAF V600 mutation-positive advanced melanoma The P-III IMspire150 study results: reduction in risk of disease worsening or death; improvement in PFS; consistent safety profile with the known profile of […]Read More

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE TN

Shots: The P-III ELEVATE TN study involves assessing of Calquence + obinutuzumab / Calquence as monothx. vs chlorambucil + obinutuzumab in 535 patients in a ratio (1:1:1) with previously untreated CLL aged ≥65yrs. or b/w 18-65yrs. with CIRS> 6 or creatinine clearance of 30-69 mL/min Results: @24mos.patients remained free of disease progression or death (93%/ […]Read More